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Abstract: AIMS: we performed this case-control observational study to evaluate the effects of early 
administration of Lactobacillus reuteri DSM 17938 on microbial composition in infants' 
gastrointestinal tract. 
METHODS: early fecal microbiota composition was analyzed by using selective and differential cultural 
methods. Genomic DNA from positive Escherichia coli and Cronobacter sakazakii colonies was 
extracted and DNA was processed by multiplex PCR assay. 
RESULTS: fecal samples of 30 hospitalized infants who previously received probiotics and 30 not 
receiving probiotics were analyzed. We find that the two groups showed differences in gut microbial 
strains composition and richness. Infant treated with probiotics have a lower total anaerobic gram-
negative counts (p=0.03) and a higher total anaerobic gram-positive counts (p=0.02). 
Enterobacteriaceae and enterococci were significantly higher (p=0.04) in the control group. No 
significant differences were observed for total aerobic counts, lactobacilli and bifidobacteria. C. 
sakazaki was found only in one infant recruited in the control group. Infants not previously treated 
with probiotics showed a higher colonization by diarrheagenic E. coli (EPEC) (p=0.04).  
CONCLUSIONS: our findings enhanced our understanding of the effects of probiotics on gut health in 
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The human gastrointestinal tract represents one of the most densely populated microbial ecosystems 
detected to date. Although this microbial group has been recognized to have a crucial impact on 
human health, its precise composition in the first period of life is still subject to intense 
investigation. Before birth, the gastrointestinal tract of the fetus is sterile, and only during the 
initiation of the delivery process and thereafter, acquisition of microbes is ongoing and time-
dependent [1, 2]. 
Initial neonatal gut colonization is a crucial stage for developing a healthy physiology, and is 
beneficially influenced by breast-feeding [3]. The colonization, development and maturation of the 
newborn gastrointestinal tract that begin immediately at birth and continue for two years, are 
modulated by numerous factors including mode of delivery, feeding regime, maternal diet/weight, 
probiotic and prebiotic use and antibiotic exposure [4, 5].  
Many other factors affect the composition of the microbiota in the intestinal tract before getting a 
stable population as in the human adult [6]. Early colonization with beneficial bacteria could help 
establish an effective ecosystem and bring about maturity in the physical structure of the gut [7]. 
Probiotic administration during the neonatal period can improve gut function by improving the 
intestinal immune status and maintaining microbial balance during gastrointestinal disturbances [7, 
8]. Although progress has been made in disclosing the mechanisms through which probiotics act on 
the intestinal immunity and microbial composition of clinical models, knowledge about the 
interaction between probiotics and intestinal microbial metabolism, as well as microbial 
composition in healthy infants, is lacking [4, 8]. Conventional studies using culture techniques 
revealed that, compared with adults, the early gut microbiota of infants has a lower proportion of 
anaerobic bacteria (especially Bacteroides and Clostridium) [2]. The sterile neonatal gut is 
colonized first by facultative anaerobic bacteria (Enterobacteriaceae, Enterococcus and 
Streptococcus) due to the abundance of oxygen. After about 1 week, the increase of these 
facultative anaerobic bacteria creates a reduced environment favorable for the establishment of 
anaerobic genera (bifidobacteria, Bacteroides and Clostridium). With time, a large number of 
anaerobic species will colonize the infant gut and multiply [1- 4]. Increasing evidence suggests that 
this process is a critical step for future child’s health and it may be influenced by environmental, 
maternal and dietary factors [5, 6]. 
Probiotics are live microorganisms that, when ingested in adequate amounts, could supply 
beneficial intestinal bacteria: many recent clinical trials suggest that this temporary colonization 
may provide health benefit [7 – 9]. Recent researches have demonstrated that probiotics can bring a 
direct action on gut microbial composition, influencing clinical outcomes in pediatric 
 
 
gastroenterology. These diseases include necrotizing enterocolitis (NEC), antibiotic-associated 
diarrhea (AAD) and colitis, infantile colic, acute gastroenteritis and irritable bowel syndrome [10 – 
13]. 
As far as skin and airways are concerned, the possible actions of probiotics need to be further 
investigated and clarified to better understand if some strains may improve conditions such as 
asthma and atopic dermatitis [14 – 16].  
Among the gastrointestinal microbiota, bifidobacteria represent an important commensal group, 
being among the first microbial colonizers of the gut [17]. However, the prevalence and diversity of 
members of the others genus in the infant intestinal microbiota has not yet been fully characterized, 
while some inconsistencies exist in literature regarding the gut health after probiotic administration 
[9 – 13]. 
The present study was conducted to evaluate the effects of early administration of Lactobacillus 
reuteri DSM 17938 on microbial composition in the gastrointestinal tract of infants using a case-
control observational study of subjects admitted at hospital during early infancy. 
 
2. MATERIALS AND METHODS: 
2.1 Selection of Subjects and study design 
From January 2013 to March 2014, 1241 infants were assessed for eligibility. 1181 infants were 
excluded because they did not fit the inclusion criteria (n=1146), parents refused to participate 
(n=25) or the amount of fecal sample was not sufficient (n=10) (Figure 1)  
The 60 eligible patients were divided into two groups (30 cases and 30 controls). 30 infants, who 
received L.reuteri DSM 17938 in the previous month (10
8
 cfu/day administered in 5 drops, once a 
day, 30 minutes before the feed in the morning), were consecutively recruited in the treatment 
group, while 30 infants who never received L.reuteri were inserted in the control group. A 
pediatrician interviewed parents to detect the assumption of probiotics. 
The control group subjects were matched to cases (1:1) by age, month of entry by a pediatrician and 
type of feeding. To prevent variability in the intestinal microbiota caused by diet, all infants 
enrolled were exclusively standard formula fed and none of them has even started weaning. 
The infants recruited had an average age of 91 ± 58 days in case group and 94 ± 53 days in control 
one. The population was divided according to sex, kind of delivery and nationality as shown in 
Table 1. 
Involved infants were hospitalized at our Department of Pediatrics (Regina Margherita Children 
Hospital, Turin, Italy). They were admitted to the hospital for various diseases: congenital 
hypothyroidism, bronchiolitis, epilepsy, urinary tract infections, gastroesophageal reflux disease, 
 
 
mononucleosis, herpes stomatitis, pneumonia, ALTE (Apparent Life-Threatening Events), poor 
growth. The following inclusion criteria were used for the selection of subjects:  
 absence of gastroenteritis; 
 no antibiotic therapy in the week before the hospitalization and until the time of sample 
collection;  
 APGAR score at 5 minutes after birth greater than 8; 
 absence of diseases due to perinatal hypoxia;  
 age < 6 months of life. 
 exclusively standard formula fed. 
The parents of the infants involved in the study were informed about the purpose of the research 
work and their written informed consent was obtained. The local ethics committee (Comitato 
Interaziendale AA.SS.OO approved the study. O.I.R.M. /S. Anna-Ordine Mauriziano di Torino) 
before the start.  
The necessary data on patients enrolled in the study were retrieved from medical records of patients 
and placed in a special enrollment cards. If data were missing, an interview was conducted with the 
parents of the patient. The following data were recorded: 
• general personal data: name and last name, date and place of birth, date of enlistment; 
• information on parents': ages and nationalities, the number and outcome of any other pregnancies; 
• reason for admission; 
• therapy in action and possible therapy in the week before hospitalization (with particular attention 
to the administration of antibiotics and / or probiotics); 
• history physiological: sex, current age, gestational age, mode of delivery, course of pregnancy , 
conditions at birth, birth weight and recruitment, type of nursing or any kind of complementary 
feeding , APGAR on the first and the fifth minute; 
• medical history: presence / absence of fever and general condition; 
• microbiological examinations carried out. 
 
2.2 Sample Collection  
Infants’ health status was recorded each afternoon and the occurrence of diarrhea was visually 
assessed [18]. 
Fecal samples were collected into a sterile Eppendorf tube under aerobic and anaerobic conditions 
and immediately transported to the microbiological laboratory of the Department of Public Health 
and Pediatric of University of Turin at +2÷6° C in a cooler for analysis. One gram of each sample 
was weighted and diluted 1:10 with normal saline solution (0.9% sodium chloride). After serial 
 
 
dilutions in normal saline, 100 l of each dilution were streaked on selective and differential media 
for bacteria isolation and identification. 
 
2.3 Microbiological analysis 
Total aerobic count on Brain Heart Infusion Agar (BHA; Biolife, Milan, Italy) was performed; 
Azide Maltose Agar (KF; Biolife, Milan, Italy) and Mac Conkey Agar (MC; Biolife, Milan, Italy) 
to detect enterococci and Enterobacteriaceae, respectively, were used. All plates were incubated at 
37°C for 24 h under aerobic conditions. The lactobacilli and bifidobacteria strains were obtained 
from Rogosa Bios Agar (RG; Biolife, Milan, Italy) after incubation at 37° C under microaerophilic 
and anaerobic conditions for 3 days, respectively. Schaedler CNA Agar with 5% Sheep Blood 
(SCNA, Becton Dickinson, NJ, USA) and Schaedler Kanamycin-Vancomycin Agar with 5% Sheep 
Blood (SKV, Becton Dickinson, NJ, USA) were used to evaluate total anaerobic gram-positive and 
gram-negative counts, respectively. All plates were incubated at 37°C for 3-7 days under anaerobic 
conditions [18]. E. coli strains were isolated using Tryptone Bile X-Gluc Agar (TBX, Biolife S.r.l., 
Milan Italy). Cronobacter sakazakii strains were detect using selective enrichment medium 
Enterobacter Sakazakii Selective Broth (ESSB, Biolife S.r.l., Milan Italy) and Enterobacter 
Sakazakii Isolation Agar plates (ESIA, Biolife S.r.l., Milan Italy). All plates were incubated at 37°C 
for 24 h under aerobic conditions. 
The microbial counts were recorded as colony forming units per gram (cfu/g) of sample. The 
qualitative analysis was performed by biochemical methods (API System, Biomérieux, Rome, 
Italy).  
 
2.4 DNA Isolation and PCR 
Genomic DNA from positive E. coli and C. sakazakii colonies was extracted with NucleoSpin 
Tissue method genomic DNA kit (MACHEREY-NAGEL GmbH & Co. KG., Düren, Germany). 
One l of DNA was processed by multiplex PCR assay. For E.coli lt and st (ETEC), eaeA and bfpA 
(EPEC), stx1 and stx2 (EHEC), ial (EIEC) genes was identified (Table 2) [19]. The reaction mixture 
was obtained with 12, 5l PCR Master Mix (2X) (Fermentas, Waltham, MA USA), 1M (each) 
primer, 1l template DNA and water nuclease-free to 25l. The thermocycle program was set up as 
follows: 5 min at 94°C; 30 cycles of 1 min at 94°C, 1 min of annealing (ranging from 55°C to 
58°C), 1 min at 72°C; 7 min at 72°C after the final cycle before cooling at 4°C. 
Primers ESSF and ESSR were designed to amplify a 469-bp fragment of the ompA gene specific to 
C. sakazakii (The sequences of PCR primer for target genes are reported in Table 2) [19]. PCR was 
performed in a 50l reaction mixture containing 25l PCR Master Mix (2X) (Fermentas, Waltham, 
 
 
MA USA), 1M (each) primer, 50 ng of template DNA and water nuclease-free to 50l. The 
samples were subjected to PCR with a program that consisted of denaturation at 94°C for 2 min 
followed by 30 cycles of 94°C for 15 s, 60°C for 15 s, and 72°C for 30 s, and a final extension at 
72°C for 5 min [20].  
The amplification products were electrophoresed through a 2% agarose gel and visualized with UV 
transilluminator after ethidium bromide staining.  















), E. coli ATCC 43893 (EIEC ial
+
) 
and C. sakazakii ATCC 51329. E. coli ATCC 25922 was used as negative control. 
 
3. Statistical Analysis  
To describe the characteristics of the studied samples, the main information was shown using 
classical descriptive indicators. Data are shown as mean ± SD for continuous variables and as 
number and percentage for categorical variables. Differences between groups were evaluated by 
Student’s t test for independent samples and associations between categorical variables were 
evaluated by Yates' chi-squared test. All reported p values are 2-sided, and differences were 
considered to be significant when p ≤ 0.05. All statistical calculations were performed with 
commercially available software (SPSS for Windows version 21.0; SPSS Inc., Chicago, IL, USA). 
 
4. RESULTS 
From January 2013 to March 2014, 60 infants were enrolled (30 previously treated with probiotics 
and 30 which received no probiotic supplementation) and their stools were collected and analyzed. 
Participants’ characteristics are reported in Table 1: the two groups do not differ for age, gender 
and type of delivery. 
We find that the two groups showed differences in gut microbial strains and richness. No 
differences were observed for total aerobic counts (p=0.49). Infant treated with probiotic showed a 
lower total anaerobic gram-negative counts (p=0.03) and a higher total anaerobic gram-positive 
counts (p=0.02). The faecal counts of Enterobacteriaceae and enterococci were found to be 
significantly higher in the control group compared with the treated group (p=0.04). No differences 
were observed for lactobacilli and bifidobacteria. Medians of microbial species amount were 
calculated and reported in Table 3. 
Among Enterobacteriaceae, E.coli was isolated in 23 of 60 stool samples analyzed (38.3%), 16 of 
these belonging to the control group (26.7%) and 7 in treated infants’ samples (11.7%) with a 
statistically significant difference (p=0.04). All E.coli strains were processed by multiplex PCR for 
 
 
the detection of virulence genes (data not shown). Four diarrheagenic E. coli (DEC) were observed 
in samples belonging to the control group (13.3%) and none in the other group. Four pathogen E. 
coli identified was atypical enteropathogenic E.coli (a-EPEC) (only eaeA gene). C. sakazaki and 
Salmonella spp. were found only in one and two respectively asymptomatic infants recruited in the 
control group (3.3% and 6.7%). C. sakazakii positive colonies were confirmed by PCR. 
Amplification of the 469-bp ompA product in this sample was observed. 
In the 60 stool samples analyzed, other potentially opportunistic pathogenic Enterobacteriaceae 
were isolated as follows: 21 Hafnia alvei, 9 Klebsiella oxytoca, 6 K.pneumoniae, 10 Enterobacter 
aerogenes, 7 E. cloacae, 3 Serratia odorifera. These microorganisms were distributed differently in 
the two groups with a significantly higher rate in no probiotic treated infants. Details about 
pathogens and opportunistic bacteria are reported in Table 4.  
 
5. DISCUSSION 
Improve our knowledge of intestinal microbiome could be useful for better understanding the roles 
of the microbial strains in promoting infants’ health [21, 22].  
Although data on gut health in infants are scanty [12, 13, 15, 16], many recent clinical trials suggest 
that probiotic administration in early infancy could be useful for the prevention and treatment of 
many disorders: modulation of the intestinal microbiota through use of probiotics has been 
suggested as strategy for preventing NEC, atopic eczema and managing infantile colic symptoms. 
Early administration of probiotics (mainly L. reuteri DSM 17938, Lactobacillus GG and 
Saccharomyces boulardii) could modulate the composition of the gut microbiota, improving 
beneficial flora and reducing potential pathogens [23]. 
This could have a significant long-time impact; however, studies with adequate follow up are 
needed.  
The timing to start the administration of probiotics may be important to maximize their 
effectiveness. 
Recent studies involving the use of culture-independent techniques have shown that 
Bifidobacterium is only a minor component of the infant gut microbiota [17]. These techniques 
have also introduced the concept of a core microbiome in which metabolic function is more 
important than the presence of a particular bacterial strain. A less various gut microbiota with high 
counts of Bacteroides, Clostridium, Enterobacteriaceae and Staphylococcus in early infancy has 
been associated with an increased risk for atopic disease [24]. Changes in infant’s gut colonization 
are also related to a higher incidence of obesity during childhood [25]. 
 
 
In this study, we have analyzed fecal samples of 30 hospitalized infants, which previously received 
probiotics, and 30 not receiving probiotics. We find that the two groups showed differences in gut 
microbial strains and richness. 
In the study, no difference was observed for total aerobic counts and for lactobacilli and 
bifidobacteria; conversely, a significant increase of total anaerobic gram-positive counts in the 
treated group compared with the control group was detected. These data suggested that the 
abundance of bifidobacteria and lactobacilli is in the typical range reported for infant fecal samples 
[26], while the increase of anaerobic gram-positive in the treated group could be due to the use of 
probiotic therapy. Moreover, the total gram-negative anaerobic bacterial count (which included 
Bacteroides spp.) in control group was moderately higher than that of the probiotic group. Studies 
demonstrated that growth of gram negative bacilli produces an increased susceptibility to 
necrotizing enterocolitis and sepsis; hence, the decrease of anaerobic gram-negative bacilli load in 
the probiotic group suggested a benefit of probiotic therapy in preventing NEC [27]. 
In the current study, L. reuteri probiotic assumption showed significant antibacterial activity against 
pathogens and opportunistic bacteria such as DEC, Salmonella spp., C. sakazakii, H. alvei, K. 
pneumoniae, K. oxytoca, E. cloacae. In fact, under anaerobic growth conditions, L. reuteri produces 
a potent antimicrobial compound called reuterin, which is a β-hydroxypropionaldehyde derivative 
of glycerol [28].  
Our results are in agreement with others who reported the antimicrobial activity of human LAB 
isolates including L. casei, L. acidophilus, L. johnsonii, L. reuteri, L. rhamnosus, and 
Bifidobacterium spp. against a wide range of foodborne pathogens [29, 30]  
In the present study, atypical EPEC was the only DEC category identified and isolated exclusively 
in the infants group who did not assume probiotics. Indeed, atypical EPEC is now predominant in 
industrial countries, while typical EPEC is more frequently isolated in developing areas [31]. This 
microorganism is associated with infantile diarrhoea, and in comparison with other pathtypes of 
diarrheagenic E. coli, it is isolated more frequently in infants less than one-year-old. The decrease 
of the infections caused by this pathogenic strain in older children could be due to acquisition of 
immunity or loss of specific receptors in the gut mucosa with increasing age. 
The percentage of EPEC found in asymptomatic infants is comparable to other studies [31, 32].  
In this work C sakazakii was isolated only in one asymptomatic infant recruited in the control group 
in agreement with others studies where this microorganism caused asymptomatic infections [33]. It 
is considered an emerging pathogen, responsible of cases of neonatal infections (sepsis, meningitis, 
necrotizing enterocolitis) related to use of contaminated infant milk formula, which can represent 
both the vehicle and the source of contamination. Powered infant formula is a non-sterile product 
 
 
which can be, once rehydrated, a good medium for microorganisms. C. sakazakii may cause 
infections in all age groups and particularly in subjects from zero to 12 months. The main source of 
diffusion and transmission to sensitive sites is the intestine; factors contributing to increase the risk 
of infection include patient’s susceptibility, level of contamination of food, tolerance to 
temperature, speed of growth, infectious dose and the virulence of the microorganism [33]. 
Salmonella spp. was isolated in two asymptomatic infants belonging to the control group. In 
humans, salmonellosis varies from a self-limiting gastroenteritis to septicemia. Whether the 
microorganism remains in the intestine or disseminates depends on host factors as well the 
virulence of the strain. Some people may be asymptomatic carriers of Salmonella spp. [34]  
This research is affected by some limitations: first, in an observational study the investigator has no 
control over the composition of the control groups, and cannot randomize the allocation of subjects. 
This could create bias, and could also mask cause and effect relationships or, alternatively, suggest 
correlations where there are none (errors in research). Second, new methods such as molecular 
identification could help us to make an assessment not only quantitative but also qualitative. 
 
6 . CONCLUSIONS  
In conclusion, one of the important functions of probiotics is their ability to inhibit the growth of 
different types of foodborne pathogens [30]; our study indicated that early administration of L. 
reuteri DSM 17938 in infancy could influence gut microbiota composition, improving gut health by 
reducing pathogens colonization. 
Further studies are needed to better understand how individual differences could act in the 
interaction between gut health and microbiota. Evaluating gut microbiota changes in addition to 
clinical outcomes in future studies concerning L. reuteri DSM 17938 effects should be helpful in 
understand how this strain influences gut health. 
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Table 1. Characteristics of participants of the infants enrolled in the study. 
 
Variable 
Cases, n (%) 
n= 30 (50.0) 
Controls, n (%) 
n= 30 (50.0) 
p value 
Mean age ± s.d. (days) 91 ± 58 94 ± 53 0.66
¶
 
Males/females, n (%) 17/13 (56.7/43.3) 20/10 (66.7/33.3) 0.60
#
 
Delivery (caesarean/spontaneous), n (%)  16/14 (53.3./46.7) 20/10 (66.7/33.3) 0.43
#
 
Nationality    
    Italian, n (%) 
    Foreign, n (%) 























Table 2. The sequences of PCR primer for target genes: details of nucleotide sequence for 
















































469 Mohan Nair et al. (2006) 
CGCCAGCGATGTTAGAAGA 
a
 gene for E.coli; 
b
 gene sequence for C. sakazakii 
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Table 3. Comparison of gut microbial counts detected in subjects who received probiotics 




No probiotic therapy 
(controls group) 
p-value 
Total aerobic counts 1.9E+09 1.7E+09 p= 0.49 
Total anaerobic gram-negative 
counts 
2.5E+06 5.3E+06 p = 0.03 
Total anaerobic gram-positive 
counts 
2.8E+07 6.5E+06 p = 0.02 
Enterobacteriaceae 6.9E+08 1.8E+09 p = 0.04 
Enterococci 6.4E+08 1.8E+09 p = 0.04 
Lactobacilli 3.8E+09 2.9E+09 p= 0.67 














OR (95%*CI) p value 
Diarrheagenic E. coli (a-EPEC) 0 (0.0) 4 (13.3) NA NA 
Salmonella spp. 0 (0.0) 2 (6.7) NA NA 
Cronobacter sakazakii 0 (0.0) 1 (3.3) NA NA 
Hafnia alvei 4 (13.3) 17 (70.0) 8.2 (2.10 - 40.39
1
) 0.001 
Klebsiella oxytoca 1 (3.3) 8 (26.7) 10.2 (1.22 - 483.7
1
) 0.03 
Klebsiella pneumoniae 1 (3.3) 5 (16.7) 6.7 (0.58 - 283.6
1
) 0.20 
Enterobacter aerogenes 2 (6.7) 8 (26.7) 5.0 (0.87 - 52.6
1
) 0.08 
Enterobacter cloacae 1 (3.3) 6 (20.0) 7.0 (0.77 - 344.7
1
) 0.11 
Serratia odorifera 0 (0.0) 3 (10.0) NA NA 
*CI, Confidence interval; NA, not applicable; 
1
 95% confidence interval 
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Assessed for eligibility 
(n = 1241) 
Excluded (n = 1181) 
 
  Not meeting inclusion criteria 
   (n = 1146) 
  Refused to participate 
   (n = 25) 
  Not adequate amount of feces (n = 10) 
Enrolled (n = 60) 
Allocated to intervention 
Probiotic 
(n = 30) 
 
Received allocated 
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